# CardiolRx™ (cardiolrx) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cardiolrx

> CardiolRx™ (cardiolrx), sponsored by Cardiol Therapeutics Inc. (CRDL): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CardiolRx™ (cardiolrx) |
| Codes |  |
| Sponsor | Cardiol Therapeutics Inc. (CRDL) https://sec-api.dev/companies/crdl/catalysts |
| Indications | acute myocarditis, with topline data, [Recurrent Pericarditis](https://sec-api.dev/indications/recurrent-pericarditis) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-24-119139): "(vi) In June 2024, the Corporation reported positive topline 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis." https://www.sec.gov/Archives/edgar/data/1702123/000110465924119139/tm2423889d1_ex99-2.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: acute myocarditis, with topline data.
- First seen 2025-04-01, last confirmed 2025-04-01.
- Press release filed with the SEC (EX-99) (accession 0001062993-25-006610): "Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis, with topline data expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1702123/000106299325006610/exhibit99-1.htm

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Recurrent Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06708299 (CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-21 (ESTIMATED); Lead Sponsor Cardiol Therapeutics Inc.." https://clinicaltrials.gov/study/NCT06708299

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Recurrent Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06708299 (CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-21 (ESTIMATED); Lead Sponsor Cardiol Therapeutics Inc.." https://clinicaltrials.gov/study/NCT06708299

## Same indication

- [KPL-387](https://sec-api.dev/pdufa/kpl-387) (KNSA)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cardiolrx.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CardiolRx™ (cardiolrx) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cardiolrx

```bibtex
@misc{secapidev_pdufa_cardiolrx_20261116,
  title        = {CardiolRx™ (cardiolrx) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cardiolrx}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cardiolrx_20261116","title":"CardiolRx™ (cardiolrx) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cardiolrx","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
